Related Experiment Video
Updated: Jul 16, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.1K
Improving Alzheimer Diagnoses With An Interpretable Deep Learning Framework: Including Neuropsychiatric Symptoms
Shujuan Liu1, Yuanjie Zheng1, Hongzhuang Li1
1School of Information Science and Engineering, Shandong Normal University, Shandong, China.
Neuroscience
|September 14, 2023
Summary
This study introduces a hybrid deep learning model for Alzheimer's disease (AD) diagnosis using MRI and clinical data. The model accurately identifies AD, highlighting apathy as a key indicator.
Area of Science:
- Neuroscience
- Artificial Intelligence
- Medical Imaging
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Neuropsychiatric symptoms (NPS) are common in AD and linked to its severity.
- Current research methods for linking NPS and AD severity lack intuitive approaches.
Purpose of the Study:
- To develop a hybrid deep learning framework for accurate Alzheimer's disease diagnosis.
- To integrate multimodal data including neuroimaging and clinical information.
- To investigate the role of specific neuropsychiatric symptoms in AD diagnosis.
Main Methods:
- A hybrid deep learning framework combining a 3D convolutional neural network (CNN) and Principal Component Analysis (PCA).
- Utilized multimodal inputs: structural MRI, behavioral scores, age, and gender.
- Employed SHapley Additive exPlanations (SHAP) for interpreting model decisions.
Main Results:
- Achieved high accuracy (0.91) and Area Under the Curve (0.97) in classifying AD from cognitively normal individuals.
- Demonstrated the model's effectiveness in integrating imaging and non-imaging data.
- Identified apathy as a significant neuropsychiatric symptom contributing to AD diagnosis.
Conclusions:
- The proposed hybrid deep learning framework offers a robust method for Alzheimer's disease diagnosis.
- Apathy emerges as a crucial factor for consideration in AD diagnosis, clinical trials, and future research.
- Multimodal data integration significantly enhances diagnostic accuracy for Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139

